Financial Crime Weekly: Pfizer Pays Nearly $60 Million To Resolve False Claims Allegations, SEC Creates Crypto Task Force

Pfizer Pays Nearly $60 Million To Resolve False Claims Allegations 
The U.S. Department of Justice announced on Friday that Pfizer Inc. (NYSE:PFE), on behalf of its subsidiary Biohaven Ltd. (NYSE:BHVN) (Biohaven), agreed to pay $59,746,277 to resolve allegations that Biohaven knowingly caused the submission of false claims to Medicare by paying kickbacks to health care providers to induce prescriptions of its drug Nurtec ODT.
The DOJ alleges that from March 1, 2020, through Sept. 30, 2022, Biohaven paid health care professionals, in the form of paid speaking appearances and expensive meals, to induce them to prescribe the medication which violates the anti-kickback statute. 
Read Next:Full story available on Benzinga.com

Read Full Article